Australia · Delayed Price · Currency is AUD Control Bionics Statistics
Total Valuation
Control Bionics has a market cap or net worth of AUD 32.59 million. The enterprise value is 31.05 million.
| Market Cap | 32.59M |
| Enterprise Value | 31.05M |
Important Dates
The last earnings date was Friday, August 28, 2026.
| Earnings Date | Aug 28, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
Control Bionics has 543.09 million shares outstanding. The number of shares has increased by 40.58% in one year.
| Current Share Class | 543.09M |
| Shares Outstanding | 543.09M |
| Shares Change (YoY) | +40.58% |
| Shares Change (QoQ) | +24.24% |
| Owned by Insiders (%) | 12.45% |
| Owned by Institutions (%) | 3.63% |
| Float | 212.41M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 6.84 |
| PB Ratio | 5.16 |
| P/TBV Ratio | 18.05 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 6.51 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 1.54, with a Debt / Equity ratio of 0.10.
| Current Ratio | 1.54 |
| Quick Ratio | 1.26 |
| Debt / Equity | 0.10 |
| Debt / EBITDA | n/a |
| Debt / FCF | -0.11 |
| Interest Coverage | -78.40 |
Financial Efficiency
Return on equity (ROE) is -122.92% and return on invested capital (ROIC) is -64.69%.
| Return on Equity (ROE) | -122.92% |
| Return on Assets (ROA) | -48.20% |
| Return on Invested Capital (ROIC) | -64.69% |
| Return on Capital Employed (ROCE) | -105.22% |
| Weighted Average Cost of Capital (WACC) | 4.91% |
| Revenue Per Employee | n/a |
| Profits Per Employee | n/a |
| Employee Count | n/a |
| Asset Turnover | 0.55 |
| Inventory Turnover | 5.60 |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +76.47% in the last 52 weeks. The beta is 0.10, so Control Bionics's price volatility has been lower than the market average.
| Beta (5Y) | 0.10 |
| 52-Week Price Change | +76.47% |
| 50-Day Moving Average | 0.06 |
| 200-Day Moving Average | 0.06 |
| Relative Strength Index (RSI) | 47.06 |
| Average Volume (20 Days) | 622,342 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, Control Bionics had revenue of AUD 4.77 million and -7.27 million in losses. Loss per share was -0.02.
| Revenue | 4.77M |
| Gross Profit | 2.36M |
| Operating Income | -6.66M |
| Pretax Income | -7.27M |
| Net Income | -7.27M |
| EBITDA | -6.00M |
| EBIT | -6.66M |
| Loss Per Share | -0.02 |
Balance Sheet
The company has 2.15 million in cash and 618,925 in debt, with a net cash position of 1.54 million or 0.00 per share.
| Cash & Cash Equivalents | 2.15M |
| Total Debt | 618,925 |
| Net Cash | 1.54M |
| Net Cash Per Share | 0.00 |
| Equity (Book Value) | 6.31M |
| Book Value Per Share | 0.02 |
| Working Capital | 1.47M |
Cash Flow
In the last 12 months, operating cash flow was -5.75 million and capital expenditures -10,037, giving a free cash flow of -5.76 million.
| Operating Cash Flow | -5.75M |
| Capital Expenditures | -10,037 |
| Depreciation & Amortization | 663,920 |
| Net Borrowing | 148,881 |
| Free Cash Flow | -5.76M |
| FCF Per Share | -0.01 |
Margins
Gross margin is 49.41%, with operating and profit margins of -139.79% and -152.42%.
| Gross Margin | 49.41% |
| Operating Margin | -139.79% |
| Pretax Margin | -152.42% |
| Profit Margin | -152.42% |
| EBITDA Margin | -125.86% |
| EBIT Margin | -139.79% |
| FCF Margin | n/a |
Dividends & Yields
Control Bionics does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -40.58% |
| Shareholder Yield | -40.58% |
| Earnings Yield | -22.30% |
| FCF Yield | -17.67% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
Control Bionics has an Altman Z-Score of -3.52 and a Piotroski F-Score of 2. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -3.52 |
| Piotroski F-Score | 2 |